CDC advisory panel opts for a go-slow approach on expanding usage of RSV vaccines
Makers of RSV vaccines for older adults saw their plans to try to expand usage hit a significant hurdle on Wednesday, when an expert committee that advises the Centers for Disease Control and Prevention on vaccines recommended changes that will likely see fewer older adults qualify for insurance coverage for these products.
In a related move, the Advisory Committee on Immunization Practices opted not to make a recommendation yet on use of GSK’s Arexvy vaccine in adults 50 to 59, saying the committee didn’t have enough data with which to make such a recommendation. Earlier this month the Food and Drug Administration approved use of the GSK vaccine to include adults in their 50s at high risk of developing severe disease if they contract respiratory syncytial virus, or RSV. When it was initially approved in May 2023, its use was restricted to people 60 and older.
